Both liraglutide and semaglutide have been shown to reduce obesity-induced muscle atrophy via a GLP-1/Sirtuin (SIRT1) pathway in rodents (40). This evidence concerns the gene GCG and obesity due to melanocortin 4 receptor deficiency.